Evaluation of clinical data of patients with pancreatic cancer

Aims: The main purpose of the study is to determine the prognostic factors by retrospectively evaluating the clinical data of patients with pancreatic cancer. Methods: The patients diagnosed with pancreatic adenocarcinoma (132) were analyzed retrospectively. Age, gender, blood group, tumour localization, tumour stage (TNM classification), postoperative chemotherapy, postoperative radiotherapy status, progression-free survival and survival time as prognostic factors were evaluated. Women and men, tumours located in the head region versus those located in the trunk and tail regions, those who received chemotherapy and/or radiotherapy versus those who did not, those who were in stage 2 The patients with stage 3, stage 4, "A" blood group, "B" blood group and "O" blood group were compared with each other and subgroup analysis was performed. Results: In our study, 59.8% were male and 40.2% were female of the cases. According to TNM staging, 34 (26%) of our cases were found as stage 2.27 (20%) as stage 3, 71 (54%) as stage 4. Progression-free survival and survival times of patients with stage 2 cancer were found to be significantly longer when compared to patients with stage 3 and 4 (p<0.01). Among stage 2 and 3 patients, 45 (38.6%) patients, 26 patients with stage 4 (19.6%) received chemotherapy, and 9 patients (6.81%) received chemotherapy and radiotherapy concurrently. The tumour was most common in the head of the pancreas [93/132 (70.5%)]. Progression-free survival and survival of tumour localization, receiving chemotherapy, and tumour stage was found to affect the duration of the study statistically significantly (p < 0.001). Conclusion: It was determined that chemotherapy and tumour stage affected progression-free survival and survival times with statistical significance. Ca 19-9 and CEA level measurement values can be used in the follow-up of patients with pancreatic cancer. EUS is usefull at pancreas cancer diagnosıs and staging.